HPV Vaccine Integrated Service Implementation Research in Cameroon
NCT06683664 · Status: NOT_YET_RECRUITING · Phase: NA · Type: INTERVENTIONAL · Enrollment: 40
Last updated 2024-11-12
Summary
The goal of this implementation research study is to understand whether a package of community-based interventions can increase access to and uptake of the human papillomavirus (HPV) vaccine among very young adolescent girls and boys in the North and Far North Regions of Cameroon. The main questions this study aims to answer are:
* Can a package of community-based interventions increase delivery of routine HPV vaccination to boys and girls aged 9-13 in Cameroon's North and Far North Regions?
* What is the acceptability, feasibility, cost, and potential for maintenance and scale of an integrated health intervention to deliver routine HPV vaccination in Cameroon?
To evaluate the effectiveness of the intervention, researchers will compare HPV vaccination within regions where the new intervention model is being implemented (intervention areas) to regions where the new routine HPV vaccination delivery model is not being implemented (comparison areas) for approximately 1 year before the new intervention model is implemented and for approximately 9 months after the start of implementation to compare changes over time and between intervention and comparison areas.
The study will evaluate the effect of the intervention on HPV vaccination delivery using routine health facility data.
To understand acceptability, feasibility, implementation, and potential for scale, the study will enroll participants including health officials and providers, adolescents girls receiving HPV vaccination and other services in intervention areas, and their parents/caregivers. The study will be conducted in two phases, with the first phase focused on gathering formative data through interviews with key informants. This data will be used to inform the design of the intervention, which will be implemented and evaluated in phase 2. Only phase 1 of this study protocol has been currently approved.
In phase 1, key informant interview participants will be asked to participate in a an interview to discuss HPV vaccination services and their perspectives on how to integrate HPV vaccination within existing community-based and health facility structures and programs. Key informants will include government officials, health program implementers, representatives from non-government organizations working on HPV vaccine delivery, and healthcare providers, as well as community leaders including school and religious leaders.
Conditions
- Papillomavirus Vaccines
- HPV Vaccinations
- HPV Vaccines
- HPV Vaccine Acceptability
- HPV Vaccine Attitudes
- HPV Vaccine Knowledge
- Adolescent Health
- Adolescent Health Services
Interventions
- OTHER
-
Integrated health service delivery for very young adolescents
The proposed HPV-PASSREV intervention will aim to increase adolescent-centered access to HPV vaccination and other very young adolescent health services through an integrated, routine, community-based delivery model that incorporates household mobilization efforts with enhanced service delivery at the health facility and community levels.
Sponsors & Collaborators
-
Fobang Institutes for Innovations in Science and Technology
collaborator UNKNOWN -
Population Services International
lead OTHER
Principal Investigators
-
Wilfred Mbacham, ScD, DS · Fobang Institutes for Innovations in Science and Technology
Study Design
- Allocation
- NON_RANDOMIZED
- Purpose
- HEALTH_SERVICES_RESEARCH
- Masking
- NONE
- Model
- PARALLEL
Eligibility
- Min Age
- 21 Years
- Sex
- ALL
- Healthy Volunteers
- Yes
Timeline & Regulatory
- Start
- 2024-11-30
- Primary Completion
- 2025-12-31
- Completion
- 2025-12-31
More Related Trials
-
KAP/WTP and HPV Prevalence Studies in a Developing World Setting (Bamako, Mali)
NCT01314404 ·Status: UNKNOWN
-
Impact of a School- and Primary Care-based Multicomponent Intervention on HPV Vaccination Acceptability
NCT04945655 ·Status: COMPLETED ·Phase: NA
-
PREVENT Pilot HPV - Related Cancers Trial
NCT06738355 ·Status: COMPLETED ·Phase: NA
-
Effectiveness of HPV Vaccine Among Adolescents and Reproductive Women
NCT06220747 ·Status: RECRUITING
-
Improving HPV Vaccination Rates Among Rural and Native American Adolescents
NCT03801603 ·Status: COMPLETED ·Phase: NA
-
Evaluating the 2-dose Immunization Schedule of Human Papillomavirus (HPV)-16/18 in Adolescent Females
NCT02740777 ·Status: COMPLETED ·Phase: PHASE2
-
A Bridging Study of a Recombinant Human Papillomavirus 16/18 Bivalent Vaccine in Preadolescent Girls
NCT02562508 ·Status: COMPLETED ·Phase: PHASE3
-
An Immuno-bridging Study of a Nonavalent HPV Vaccine (E.Coli) in Healthy Population Aged 9-17 vs Aged 18-26 Years Old
NCT05056402 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE3
-
Clinical Decision Support Tools to Increase Human Papillomavirus (HPV) Vaccination in Adolescents in Pharmacies
NCT05831540 ·Status: TERMINATED ·Phase: NA
-
Long-term Effectiveness and Immuno-persistence Study of a Recombinant HPV 16/18 Bivalent Vaccine in Preadolescent Girls
NCT06243666 ·Status: ACTIVE_NOT_RECRUITING
-
Human Papillomavirus Screening and Vaccine Readiness Program
NCT00863096 ·Status: WITHDRAWN
-
Two Domestic HPV Vaccines and Imported HPV Vaccines in Women Aged 13-14 Years Study on Immunogenicity
NCT06137352 ·Status: NOT_YET_RECRUITING
-
A Study to Compare the Impact of a School Based HPV Program on Vaccination Uptake and Completion Rates
NCT01526551 ·Status: COMPLETED ·Phase: NA
-
Can an Educational Intervention Targeting General Practitioners Increase HPV Vaccination Coverage in AuRA_Lyon (France)
NCT03592225 ·Status: UNKNOWN ·Phase: NA
-
Immuno-persistence Study of a Recombinant Human Papillomavirus 16/18 Bivalent Vaccine in Preadolescent Girls
NCT03206255 ·Status: COMPLETED
-
Effectiveness of Single Dose or Two Doses of Bivalent HPV Vaccine in Thailand
NCT03747770 ·Status: UNKNOWN ·Phase: NA
-
Study to Test the Safety of HPV Vaccine in Women (V501-011)(COMPLETED)
NCT00517309 ·Status: COMPLETED ·Phase: PHASE3
-
The STOP-HPV Trial 5: Single Arm Evaluation of the Bundle
NCT03609320 ·Status: UNKNOWN ·Phase: NA
-
Provider Recommendation and HPV Vaccination
NCT05365048 ·Status: RECRUITING ·Phase: NA
-
HPV Vaccination in HIV Infected and HIV Uninfected Adolescents in Eswatini
NCT04982614 ·Status: COMPLETED ·Phase: PHASE4
-
STI Knowledge and HPV Vaccine Acceptance in Bamako, Mali in 2012
NCT05767138 ·Status: COMPLETED
-
IMPAACT P1085: Human Papilloma Virus (HPV) Type-Specific Antibody
NCT01206556 ·Status: COMPLETED
-
Tolerability and Immunogenicity of Gardasil in Females Between 16 and 23 Years of Age in India (V501-034)
NCT00733122 ·Status: WITHDRAWN ·Phase: PHASE3
-
Effectiveness, Safety and Immunogenicity of GSK Biologicals' HPV Vaccine GSK580299 (Cervarix) Administered in Healthy Adolescents
NCT00534638 ·Status: COMPLETED ·Phase: PHASE4
-
HPV Ends Here: Increasing Uptake of the HPV Vaccine
NCT06831929 ·Status: RECRUITING ·Phase: NA